SCHEMBL12596089

SCHEMBL12596089

Cn1c2ccccc2c2cc(N(c3ccccc3)c3c4ccccc4c(N(c4ccccc4)c4ccc5c(c4)c4ccccc4n5C)c4ccccc34)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.50
KDM4E B2RXH2 7/20 0.49
HPGD P15428 8/20 0.47
ALDH1A1 P00352 7/20 0.47
MAPT P10636 5/20 0.47
HSD17B10 Q99714 4/20 0.47
MEN1 O00255 2/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PABPC1 P11940 1/20 0.43
KIF11 P52732 1/20 0.40
NPY5R Q15761 1/20 0.39
LMNA P02545 2/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12559383 0.92 GPR3 (0.55) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL12249804 0.92 GPR3 (0.55) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL12596052 0.92 KDM4E (0.43) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL16696178 0.87 GPR3 (0.45) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL12559418 0.87 GPR3 (0.45) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL26242812 0.86 GPR3 (0.48) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL18564772 0.86 GPR3 (0.48) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL12249697 0.86 GPR3 (0.48) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL17904083 0.84 KDM4E (0.44) GPR3KDM4EHPGDALDH1A1MAPT
SCHEMBL12596092 0.84 KDM4E (0.34) GPR3KDM4EHPGDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066629-B1 ANTHRACENE DERIVATIVE, AND LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LAB (JP) 2017-05-17 EP disclosed
US-8546792-B2 Anthracene derivative, and light emitting element, light emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-10-01 US disclosed
US-8546792-B2 Anthracene derivative, and light emitting element, light emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-10-01 US disclosed
US-20110121275-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-05-26 US disclosed
US-7880019-B2 9-[N-phenyl-N-(9-phenylcarbazol-3-yl)amino]-10-phenylanthracene; high luminous efficiency; long lifetime SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-02-01 US disclosed
US-7880019-B2 9-[N-phenyl-N-(9-phenylcarbazol-3-yl)amino]-10-phenylanthracene; high luminous efficiency; long lifetime SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-02-01 US disclosed
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-04-10 US disclosed
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-04-10 US disclosed
WO-2008038607-A1 ANTHRACENE DERIVATIVE, AND LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative GLB1, CYP1A1, XPOT GPR3 3992/4885KDM4E 3720/4885HPGD 196/4885
US-20110121275-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Anthracene Derivative GLB1, CYP1A1, XPOT GPR3 3992/4885KDM4E 3720/4885HPGD 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.